Nordson Corporation (NDSN) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A indicate a positive outlook with strong operational execution, margin maintenance, and share repurchase plans. Despite some uncertainties, guidance suggests improvement, especially in the IPS and ATS segments. The company's capital deployment strategy and healthy growth drivers in medical and technology segments further bolster positive sentiment. While there are challenges, the overall sentiment leans towards a positive stock price movement over the next two weeks.
Key Financial Performance
Sales (Q4 2025) $752 million, up 1% compared to the prior year's fourth quarter sales of $744 million. Organic sales decreased 1%, with growth in the Medical segment offset by softness in Industrial and Advanced Technology systems product lines. Currency translation had a positive impact of 2%.
Adjusted Earnings Per Share (Q4 2025) $3.03, a 9% increase over the prior year. This reflects strong operational performance and improved portfolio mix due to the divestiture of the medical contract manufacturing business.
EBITDA (Q4 2025) $256 million, up 6% year-over-year, representing 34% of sales. This is a 160 basis point improvement over the prior year, driven by operational performance, portfolio mix improvement, and restructuring actions.
Cash Flow (Q4 2025) $194 million, a record with a conversion rate to net income of 128%. This enabled share repurchases, dividend payments, and debt reduction.
Sales (Fiscal Year 2025) $2.8 billion, up 4% from last year. Organic sales were down 3%, but acquisition and divestiture activity added a net 6% to sales. Currency provided a modest benefit.
Adjusted Earnings Per Share (Fiscal Year 2025) $10.24, up 5% from the prior year, exceeding the midpoint of initial full-year guidance.
Gross Margins (Fiscal Year 2025) Maintained at 55%, demonstrating value and differentiation despite an evolving tariff environment.
EBITDA (Fiscal Year 2025) $900 million, up 6%, achieving the 2025 Ascend Strategy goal. This reflects a full-year incremental EBITDA margin of 49%.
Free Cash Flow (Fiscal Year 2025) $661 million, a record with a cash conversion rate of 136% on net income. This enabled $300 million in share repurchases, $179 million in dividends, and $224 million in net debt reduction.
Industrial Precision Solutions Sales (Q4 2025) $362 million, down 2% compared to the prior year. Organic sales decreased 4%, with currency providing a 2% favorable impact. Declines in polymer processing and industrial coating systems were offset by growth in precision agriculture and packaging product lines.
Medical and Fluid Solutions Sales (Q4 2025) $220 million, up 10% compared to the prior year. Organic sales increased 7%, driven by broad-based demand. EBITDA was $88 million, or 40% of sales, up 21% year-over-year.
Advanced Technology Solutions Sales (Q4 2025) $171 million, down 4% compared to the prior year. Organic sales decreased 5%, with a small positive currency benefit. Weakness in x-ray systems demand overshadowed growth in electronic dispense product lines.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Atrion Medical Integration: The integration of Atrion Medical has been successful, contributing to sales and EPS growth in its first year.
Medical Portfolio Optimization: Divestiture of the medical contract manufacturing business improved margins and increased focus on differentiated medical businesses.
Advanced Technology Solutions (ATS): Strong growth in electronic dispense product lines and stable demand for optical and acoustic product lines, though offset by weakness in x-ray systems.
Geographic Expansion in Precision Agriculture: Sustained demand in Europe and South America for precision agriculture due to increasing yields and quality.
Semiconductor Applications: Positioned to benefit from investments in semiconductor cycles, particularly in advanced packaging applications for AI and cloud computing.
EBITDA Margin Improvement: Achieved record EBITDA of $256 million in Q4, with a margin of 34%, driven by operational performance and portfolio optimization.
Free Cash Flow Conversion: Achieved a record free cash flow conversion rate of 136% of net income, enabling share repurchases, dividend increases, and debt reduction.
Restructuring Actions: Completed restructuring actions announced earlier in the year, contributing to improved margins.
Ascend Strategy: Achieved 2025 Ascend Strategy goal with $900 million in EBITDA, focusing on leadership in niche markets and operational excellence.
Long-term Growth Targets: Set targets for 6%-8% annual revenue growth and 10%-12% adjusted EPS growth from 2025 to 2029.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Organic Sales Decline: Organic sales decreased 1% in Q4 2025 compared to Q4 2024, with declines in Industrial and Advanced Technology systems product lines.
Segment-Specific Weakness: Weakness in polymer processing systems, automotive-related systems, and selected X-ray inspection applications weighed down organic sales for the year.
X-ray Systems Demand: Advanced Technology Solutions segment experienced a 4% sales decline in Q4 2025, driven by weakness in X-ray systems demand.
Unfavorable Product Mix: Advanced Technology Solutions segment faced a decrease in EBITDA margin due to lower sales volume and unfavorable product mix.
Macroeconomic Disruptions: The company navigated through significant macroeconomic changes, which could pose risks to stability and growth.
Dynamic Trade Environment: Challenges in the trade environment required operational adjustments to maintain margins.
Currency Translation Impact: Currency translation had a mixed impact, with a 2% positive effect in Q4 2025 but potential volatility in future periods.
Restructuring Actions: Restructuring actions, while improving margins, indicate underlying challenges in optimizing operations.
Divestiture Impact: The divestiture of the medical contract manufacturing business improved margins but reduced overall sales.
Lumpy Semiconductor Orders: Semiconductor applications, which account for 50% of ATS revenue, face lumpy order timing, creating revenue unpredictability.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: Full year sales for fiscal 2026 are expected to grow in the range of 1% to 6% above fiscal 2025 sales, with a midpoint of 3.5% growth. This includes a 1% benefit from foreign exchange rates, offset by the divested medical contract manufacturing business.
Earnings Growth: Adjusted earnings per share for fiscal 2026 are forecasted to grow in the range of 6% to 12%, with a midpoint of 9% growth.
Segment Performance - Industrial Precision Solutions (IPS): The IPS segment is expected to return to low single-digit growth rates, driven by stable demand in packaging, product assembly, and precision agriculture markets. Demand in auto and polymer processing end markets has stabilized.
Segment Performance - Medical: The Medical segment is projected to achieve mid-single-digit organic growth, supported by consistent demand drivers such as aging population and non-invasive surgeries. Customer destocking is no longer a factor.
Segment Performance - Advanced Technology Solutions (ATS): ATS is expected to benefit from investments in semiconductor applications, which account for approximately 50% of ATS revenue. Demand in automotive and general electronics is stable but dampens higher semiconductor growth rates.
Backlog: The company enters fiscal 2026 with approximately $600 million in backlog, up 5% from the prior year-end, excluding the divested business.
Capital Expenditures: Capital expenditures for fiscal 2026 are estimated to be approximately $55 million to $65 million.
Tax Rate: The effective tax rate for fiscal 2026 is estimated to be in the range of 18.5% to 19.5%.
Interest Expense: Interest expense for fiscal 2026 is projected to be approximately $85 million to $95 million.
First Quarter Fiscal 2026 Guidance: First quarter fiscal 2026 sales are forecasted in the range of $630 million to $670 million, with adjusted earnings in the range of $2.25 to $2.45 per diluted share.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividend Payments: Increased dividends for the 62nd consecutive year, amounting to $179 million in fiscal 2025.
Share Repurchase: Repurchased approximately $300 million in shares during fiscal 2025.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Are you seeing any broadening out across the semiconductor applications yet? Or is it still concentrated in areas like data center, AI, and cloud computing?
A:The strength continues in the semiconductor space for AI applications, cloud computing, and such. Automotive is starting to stabilize, and general electronics has been decent but with lower growth compared to semiconductor growth rates. Revenue breakdown: 50% from semiconductors, 15% from automotive, and the rest from electronics.
Q:Are the current margin levels representative to build off of for the next year?
A:For IPS and ATS, the current margins are in line with historical performance and are a good jump-off point. For the Medical segment, upper 30% margins are sustainable, though the 40% achieved this quarter is notable and not expected to be consistent. A 100 basis point improvement in segment margins is expected due to divestiture actions.
Q:What are your expectations for polymer processing versus the rest of the IPS business in 2026?
A:Polymer processing has likely hit the bottom, and expectations are for improvement going into the year. It is not expected to be a drag on IPS anymore.
Q:What is driving the healthy growth implied in ATS for Q1?
A:Growth is driven by stable demand, particularly in the semiconductor space, as well as electronics, automotive, and general electronics. Favorable year-over-year comparisons due to a slow start last year and a stronger backlog entering the year are also contributing factors.
Q:Can you elaborate on the trends in the X-ray Inspection business and its relation to semiconductor growth?
A:The X-ray business has exposure to both semiconductors and automotive. Differences in performance are partly due to automotive exposure. New product launches are expected to contribute to growth. Technological transitions in testing are ongoing, with new technologies expected to impact in 2027. The X-ray business is in a good position to contribute to ATS growth this year.
Q:What is the M&A strategy and approach to share buybacks?
A:The M&A strategy focuses on adding highly differentiated businesses that enhance portfolio growth while remaining strategically and financially disciplined. The company has a robust pipeline but did not execute any deals in 2025 due to strategic or financial criteria. Share buybacks are balanced with acquisitions, and the company sees upside in its stock price.
Q:Why does the low end of the guidance range assume minimal growth despite signs of market stabilization?
A:The guidance range accounts for a range of potential outcomes, including hypothetical downside scenarios. While the company sees indicators of stabilization and expects a strong start to the year, it is prudent to plan for potential market uncertainties.
Q:How does the IPS segment relate to industrial production and PMI factors?
A:The IPS segment was weighed down by polymer processing and automotive in 2025, but core IPS businesses like packaging, product assembly, and precision agriculture showed growth. With polymer processing and automotive having troughed, the segment is expected to return to GDP-plus growth in 2026.
Q:Does the lumpiness of electronic processing systems orders affect the annual performance of ATS?
A:While there may be peaks and valleys in quarterly performance due to delivery timing, the ATS segment is expected to show mid-single-digit growth over a 12-month period, consistent with its long-term growth trajectory.
Q:What are the expectations for polymer processing and automotive businesses in 2026?
A:Both polymer processing and automotive businesses have likely troughed. Nominal growth is expected, and any significant recovery would provide upside to the guidance range.
Q:How has backlog trended sequentially and year-over-year?
A:Backlog is up 5% year-over-year but down sequentially, which is normal due to seasonal factors like holidays. The year-over-year increase indicates a stronger starting position for the year.
Q:What is the expected seasonality for revenue and EBITDA in 2026?
A:Normal seasonality is expected, with Q1 being the lowest quarter due to holidays and year-end timing. Sequential improvement is anticipated throughout the year.
Q:What are the key achievements and challenges of the NBS Next strategy over the past five years?
A:NBS Next has driven strategic discipline, segmentation, and growth. EBITDA margins improved from 27% to 32% over five years. The focus is now on commercial excellence to connect segmentation, innovation, and operational excellence. The company sees significant growth opportunities ahead.
Q:What inning is the company in regarding operational EBITDA improvements under NBS Next?
A:The company is focused on growth as the primary driver of margin enhancement. Long-term, a 35% incremental margin is expected, with current margins at 32%. Growth in a profitable way remains the key focus.
Q:What bridges the midpoint of EPS guidance to the upper end of the long-term target range?
A:Stronger growth in the base business and potential acquisitions could drive EPS growth to the upper end of the range. The guidance does not currently factor in acquisitions, but they remain a possibility.
Q:Are the working capital improvements sustainable, and is there room for further improvement?
A:Yes, the working capital improvements are sustainable, and the company sees additional opportunities for further enhancement.
Q:Review of Unclear Management Responses
A:Management avoided giving a direct answer to the question about whether they are still buyers in the open market at the current stock price. They emphasized a balanced approach to capital allocation but did not provide a clear stance on open market purchases.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ATS market
ATS system
Ascend capability
Ascend result
Ascend year
Communications Vice
IPS currency
Inspection application
Medical success
Nordson commitment
Nordson strength
Sales divestiture
Slide progress
Solutions sale
ability opportunity
acquisition divestiture
backlog order
benefit sale
cash conversion
coating system
contract manufacturing
currency benefit
decrease sale
demand product
divestiture contract
dividend debt
flow generation
income cash
line demand
manufacturing sale
manufacturing share
mix
order rate
ray system
record cash
record sale
record share
result sale
sale basis
sale decrease
share dividend
weakness ray
NDSN Transcript
Nordson Corporation (NDSN) Q2 2026 Earnings Call Transcript
Neutral5-21
Nordson Corporation (NDSN) Q1 2026 Earnings Call Transcript
Positive2-19
The earnings call summary indicates stable to positive growth across segments, with notable strength in the medical and ATS segments. The Q&A reveals confidence in overcoming weather impacts and a strong order pipeline. Despite some margin challenges, management maintains a positive outlook with strong incrementals. The company's strategic focus on high-margin areas and disciplined M&A activity further supports a positive sentiment. Overall, the insights suggest a positive market reaction, likely within the 2% to 8% range.
Empire Company Limited (EMP.A:CA) Q2 2026 Earnings Call Transcript
Positive12-11
The earnings call presents a positive outlook with 12.5% EPS growth and strategic initiatives like technology investments and disciplined cost management. The Q&A highlights a focus on profitability, e-commerce growth, and leveraging partnerships, despite avoiding specifics on e-commerce penetration. The company's commitment to share repurchases and operational improvements further supports a positive sentiment. However, the lack of specific guidance on e-commerce penetration and current performance ratings introduces some uncertainty. Overall, the strategic focus and financial health suggest a positive stock price movement.
Nordson Corporation (NDSN) Q4 2025 Earnings Call Transcript
Positive12-11
The earnings call summary and Q&A indicate a positive outlook with strong operational execution, margin maintenance, and share repurchase plans. Despite some uncertainties, guidance suggests improvement, especially in the IPS and ATS segments. The company's capital deployment strategy and healthy growth drivers in medical and technology segments further bolster positive sentiment. While there are challenges, the overall sentiment leans towards a positive stock price movement over the next two weeks.
NDSN Slides
NDSN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
